Back
ESC2025 Premium Access

Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis

Session: Drug therapy (2)
Topic: Drug therapy
Speaker: Doctor C. Bonanad Lozano (Valencia, ES)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Clara Bonanad Lozano

Instituto de Investigacion Sanitaria INCLIVA, Valencia (Spain)
4 presentations
1 follower

7 more presentations in this session

Bempedoic acid in clinical practice.

Speaker: Doctor J. Vazquez Reguera (Las Palmas de Gran Canaria, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study

Speaker: Assistant Professor Z. Yang (Shatin, HK)

Access
Abstract
Slides
Video
Like
Thumbnail

Efficacy and safety of add on bempedoic acid on maximal dose of rosuvastatin and ezetimibe in patients with established coronary artery disease (ADDBAMPIRE study)

Speaker: Professor N. Garg (Lucknow, IN)

Access
Abstract
Slides
Video
Like
Thumbnail

LDL on target - strike early and strike strong... just strike...

Speaker: Doctor L. Hamann (Faro, PT)

Access
Abstract
Slides
Video
Like
Thumbnail

VICTORION IMPLEMENT: an observational study of the lipid management landscape in Germany

Speaker: Professor O. Weingaertner (Jena, DE)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Drug therapy (2)

Speakers: Doctor C. Bonanad Lozano, Doctor J. Vazquez Reguera, Assistant Professor Z. Yang, Professor N. Garg, Doctor L. Hamann...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources